PRTC
Puretech Health

113
Mkt Cap
$408.69M
Volume
900.00
52W High
$23.35
52W Low
$13.30
PE Ratio
9.28
PRTC Fundamentals
Price
$16.91
Prev Close
$16.81
Open
$16.92
50D MA
$17.23
Beta
0.35
Avg. Volume
4,930.26
EPS (Annual)
$2.10
P/B
1.08
Loading...
Loading...
News
all
press releases
News Placeholder
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today...
Business Wire·4d ago
News Placeholder
PureTechs Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes...
Business Wire·7d ago
News Placeholder
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today...
Business Wire·2mo ago
News Placeholder
What Makes PureTech Health (PRTC) a New Buy Stock
PureTech Health (PRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago

Latest PRTC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.